Genetics of FTLD: overview and what else we can expect from genetic studies

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 32-53

  Pottier, Cyril ^a   Ravenscroft, Thomas A ^a   Sanchez Contreras, Monica ^a   Rademakers, Rosa ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

C9orf72; frontotemporal lobar degeneration; genetics; MAPT; progranulin; TMEM106B

Indexed keywords

FUSED IN SARCOMA PROTEIN; OPTINEURIN; PROGRANULIN; TAR DNA BINDING PROTEIN; VALOSIN CONTAINING PROTEIN;

C9ORF72 GENE; CHCHD10 GENE; CHMP2B GENE; DISEASE COURSE; FAMILY HISTORY; FRONTOTEMPORAL DEMENTIA; FUS GENE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; HNRNPA1 GENE; HNRNPA2B1 GENE; HUMAN; MICROTUBULE ASSOCIATED TAU GENE; MOLECULAR PATHOLOGY; NONHUMAN; OPTINEURIN GENE; PRIORITY JOURNAL; PROGRANULIN GENE; REVIEW; RISK ASSESSMENT; SQSTM1 GENE; TANK BINDING KINASE 1 GENE; TDP 43 GENE; TMEM106B GENE; VALOSIN CONTAINING PROTEIN GENE;

EID: 84981165220     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13622     Document Type: Review

References (236)

1. Ahmad S. T., Sweeney S. T., Lee J.-A., Sweeney N. T. and Gao F.-B. (2009) Genetic screen identifies serpin5 as a regulator of the toll pathway and CHMP2B toxicity associated with frontotemporal dementia. Proc. Natl Acad. Sci. USA 106, 12168–12173.
2. Ahmed Z., Sheng H., Xu Y. F. et al. (2010) Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am. J. Pathol. 177, 311–324.
3. Alexander A. G., Marfil V. and Li C. (2014) Use of C. elegans as a Model to Study Alzheimer's Disease and other neurodegenerative diseases. Fron. Genet. 5, 279.
4. Andreadis A., Brown W. M. and Kosik K. S. (1992) Structure and novel exons of the human tau gene. Biochemistry 31, 10626–10633.
5. Aoki N., Murray M. E., Ogaki K., Fujioka S., Rutherford N. J., Rademakers R., Ross O. A. and Dickson D. W. (2015) Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A. Acta Neuropathol. 129, 53–64.
6. Ash P. E., Bieniek K. F., Gendron T. F. et al. (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639–646.
7. Babst M., Katzmann D. J., Estepa-Sabal E. J., Meerloo T. and Emr S. D. (2002) ESCRT-III: An endosome-associated heterooligomeric protein complex required for MVB sorting. Dev. Cell 3, 271–282.
8. Baker M., Mackenzie I. R., Pickering-Brown S. M. et al. (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916–919.
9. Bang J., Spina S. and Miller B. L. (2015) Frontotemporal dementia. Lancet 386, 1672–1682.
10. Bannwarth S., Ait-El-Mkadem S., Chaussenot A. et al. (2014) A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 137, 2329–2345.
11. Beck J., Rohrer J. D., Campbell T. et al. (2008) A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain 131, 706–720.
12. Belzil V. V., Bauer P. O., Prudencio M. et al. (2013) Reduced C9orf72 gene expression in c9FTD/ALS is caused by histone trimethylation, an epigenetic event detectable in blood. Acta Neuropathol. 126, 895–905.
13. Benussi A., Padovani A. and Borroni B. (2015) Phenotypic heterogeneity of monogenic frontotemporal dementia. Front. Aging Neurosci. 7, 171.
14. van Blitterswijk M. and Rademakers R. (2015) Neurodegenerative disease: C9orf72 repeats compromise nucleocytoplasmic transport. Nat. Rev. Neurol. 11, 670–672.
15. van Blitterswijk M., DeJesus-Hernandez M. and Rademakers R. (2012a) How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? Curr. Opin. Neurol. 25, 689–700.
16. van Blitterswijk M., van Es M. A., Hennekam E. A. et al. (2012b) Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum. Mol. Genet. 21, 3776–3784.
17. van Blitterswijk M., Baker M. C., DeJesus-Hernandez M. et al. (2013a) C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology 81, 1332–1341.
18. van Blitterswijk M., DeJesus-Hernandez M., Niemantsverdriet E. et al. (2013b) Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 12, 978–988.
19. van Blitterswijk M., Mullen B., Heckman M. G. et al. (2014a) Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiol. Aging 35, 2421, e2413–2427.
20. van Blitterswijk M., Mullen B., Nicholson A. M. et al. (2014b) TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathol. 127, 397–406.
21. van Blitterswijk M., Mullen B., Wojtas A. et al. (2014c) Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Mol. Neurodegener. 9, 38.
22. van Blitterswijk M., Gendron T. F., Baker M. C. et al. (2015) Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. Acta Neuropathol. 130, 863–876.
23. Boeve B. F., Boylan K. B., Graff-Radford N. R. et al. (2012) Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain 135, 765–783.
24. Boxer A. L., Mackenzie I. R., Boeve B. F. et al. (2011) Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J. Neurol. Neurosurg. Psychiatry 82, 196–203.
25. Brady O. A., Zheng Y., Murphy K., Huang M. and Hu F. (2013) The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function. Hum. Mol. Genet. 22, 685–695.
26. Brandt R., Hundelt M. and Shahani N. (2005) Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim. Biophys. Acta 1739, 331–354.
27. Bruni A. C., Momeni P., Bernardi L. et al. (2007) Heterogeneity within a large kindred with frontotemporal dementia: a novel progranulin mutation. Neurology 69, 140–147.
28. Buee L. and Delacourte A. (1999) Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease. Brain Pathol. 9, 681–693.
29. Cady J., Allred P., Bali T. et al. (2015) Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann. Neurol. 77, 100–113.
30. Capell A., Liebscher S., Fellerer K. et al. (2011) Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. J. Neurosci. 31, 1885–1894.
31. Carrasquillo M. M., Nicholson A. M., Finch N. et al. (2010) Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma. Am. J. Hum. Genet. 87, 890–897.
32. Cenik B., Sephton C. F., Dewey C. M. et al. (2011) Suberoylanilide hydroxamic acid (vorinostat) up-regulates progranulin transcription: rational therapeutic approach to frontotemporal dementia. J. Biol. Chem. 286, 16101–16108.
33. Chaussenot A., Le Ber I., Ait-El-Mkadem S. et al. (2014) Screening of CHCHD10 in a French cohort confirms the involvement of this gene in frontotemporal dementia with amyotrophic lateral sclerosis patients. Neurobiol. Aging 35, 2884, e2881–2884.
34. Chen-Plotkin A. S., Unger T. L., Gallagher M. D. et al. (2012) TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways. J. Neurosci. 32, 11213–11227.
35. Chew J., Gendron T. F., Prudencio M. et al. (2015) Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 348, 1151–1154.
36. Cirulli E. T., Lasseigne B. N., Petrovski S. et al. (2015) Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 347, 1436–1441.
37. Ciura S., Lattante S., Le Ber I., Latouche M., Tostivint H., Brice A. and Kabashi E. (2013) Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann. Neurol. 74, 180–187.
38. Clayton E. L., Mizielinska S., Edgar J. R. et al. (2015) Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology. Acta Neuropathol. 130, 511–523.
39. Cooper-Knock J., Walsh M. J., Higginbottom A. et al. (2014) Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain 137, 2040–2051.
40. Cooper-Knock J., Kirby J., Highley R. and Shaw P. J. (2015) The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis. Neurotherapeutics 12, 326–339.
41. Coppola G., Chinnathambi S., Lee J. J. et al. (2012) Evidence for a role of the rare p. A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum. Mol. Genet. 21, 3500–3512.
42. Crary J. F., Trojanowski J. Q., Schneider J. A. et al. (2014) Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 128, 755–766.
43. Cruchaga C., Graff C., Chiang H. H. et al. (2011) Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels. Arch. Neurol. 68, 581–586.
44. Cruts M., Rademakers R., Gijselinck I., van der Zee J., Dermaut B., de Pooter T., de Rijk P., Del-Favero J. and van Broeckhoven C. (2005) Genomic architecture of human 17q21 linked to frontotemporal dementia uncovers a highly homologous family of low-copy repeats in the tau region. Hum. Mol. Genet. 14, 1753–1762.
45. Cruts M., Gijselinck I., van der Zee J. et al. (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920–924.
46. Cruts M., Engelborghs S., dervan Zee J., Van Broeckhoven C. (2015) C9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia, in GeneReviews (R), (Pagon R. A., Adam M. P. and Ardinger H. H. et al. eds.), Seattle (WA).
47. DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F. et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245–256.
48. Deng H.-X., Chen W., Hong S.-T. et al. (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211–U113.
49. Denk F. and Wade-Martins R. (2009) Knock-out and transgenic mouse models of tauopathies. Neurobiol. Aging 30, 1–13.
50. Dickson D. W., Kouri N., Murray M. E. and Josephs K. A. (2011) Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J. Mol. Neurosci. 45, 384–389.
51. Dillen L., Van Langenhove T., Engelborghs S. et al. (2013) Explorative genetic study of UBQLN2 and PFN1 in an extended Flanders-Belgian cohort of frontotemporal lobar degeneration patients. Neurobiol. Aging 34, 1711.e1–1711.e5.
52. Dols-Icardo O., Nebot I., Gorostidi A. et al. (2015) Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain 138, e400.
53. Donnelly C. J., Zhang P. W., Pham J. T. et al. (2013) RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415–428.
54. Dormann D. and Haass C. (2013) Fused in sarcoma (FUS): an oncogene goes awry in neurodegeneration. Mol. Cell Neurosci. 56, 475–486.
55. Dormann D., Madl T., Valori C. F. et al. (2012) Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 31, 4258–4275.
56. Edbauer D. and Haass C. (2015) An amyloid-like cascade hypothesis for C9orf72 ALS/FTD. Curr. Opin. Neurobiol. 36, 99–106.
57. Farg M. A., Sundaramoorthy V., Sultana J. M. et al. (2014) C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet. 23, 3579–3595.
58. Farrer M. J., Hulihan M. M., Kachergus J. M. et al. (2009) DCTN1 mutations in Perry syndrome. Nat. Genet. 41, 163–165.
59. Fecto F., Yan J., Vemula S. P. et al. (2011) SQSTM1 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis. Arch. Neurol. 68, 1440–1446.
60. Ferrari R., Hernandez D. G., Nalls M. A. et al. (2014) Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurol. 13, 686–699.
61. Ferrari R., Grassi M., Salvi E. et al. (2015) A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. Neurobiol. Aging 36, 2904, e2913–2926.
62. Filiano A. J., Martens L. H., Young A. H. et al. (2013) Dissociation of frontotemporal dementia-related deficits and neuroinflammation in progranulin haploinsufficient mice. J. Neurosci. 33, 5352–5361.
63. Finch N., Baker M., Crook R. et al. (2009) Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. Brain 132, 583–591.
64. Finch N., Carrasquillo M. M., Baker M. et al. (2011) TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology 76, 467–474.
65. Foster N. L., Wilhelmsen K., Sima A. A., Jones M. Z., D'Amato C. J. and Gilman S. (1997) Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann. Neurol. 41, 706–715.
66. Freischmidt A., Wieland T., Richter B. et al. (2015) Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 18, 631–636.
67. Galimberti D., Reif A., Dell'osso B. et al. (2014) C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. Neurobiol. Aging, 35, 1214 e1217-1214 e1210.
68. Gallagher M. D., Suh E., Grossman M. et al. (2014) TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathol. 127, 407–418.
69. Galluzzi L., Kepp O. and Kroemer G. (2011) Autophagy and innate immunity ally against bacterial invasion. EMBO J. 30, 3213–3214.
70. Gass J., Cannon A., Mackenzie I. R. et al. (2006) Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum. Mol. Genet. 15, 2988–3001.
71. Gass J., Lee W. C., Cook C. et al. (2012) Progranulin regulates neuronal outgrowth independent of sortilin. Mol. Neurodegener. 7, 33.
72. Gendron T. F., Josephs K. A. and Petrucelli L. (2010) Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. Neuropathol. Appl. Neurobiol. 36, 97–112.
73. Gendron T. F., Bieniek K. F., Zhang Y. J. et al. (2013) Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 126, 829–844.
74. Gendron T. F., Belzil V. V., Zhang Y. J. and Petrucelli L. (2014) Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol. 127, 359–376.
75. Gendron T. F., van Blitterswijk M., Bieniek K. F. et al. (2015) Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathol. 130, 559–573.
76. Genin E. C., Plutino M., Bannwarth S. et al. (2015) CHCHD10 mutations promote loss of mitochondrial cristae junctions with impaired mitochondrial genome maintenance and inhibition of apoptosis. EMBO Mol. Med. 8, 58–72.
77. Ghazi-Noori S., Froud K. E., Mizielinska S. et al. (2012) Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain 135, 819–832.
78. Ghetti B., Oblak A. L., Boeve B. F., Johnson K. A., Dickerson B. C. and Goedert M. (2015) Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol. Appl. Neurobiol. 41, 24–46.
79. Ghidoni R., Benussi L., Glionna M., Franzoni M. and Binetti G. (2008) Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology 71, 1235–1239.
80. Gijselinck I., Van Broeckhoven C. and Cruts M. (2008) Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update. Hum. Mutat. 29, 1373–1386.
81. Gijselinck I., Van Mossevelde S., van der Zee J. et al. (2015) Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology 85, 2116–2125.
82. Gistelinck M., Lambert J.-C., Callaerts P., Dermaut B. and Dourlen P. (2012) Drosophila models of tauopathies: what have we learned? Int. J. Alzheimer's Dis. 2012, 14.
83. Goedert M. and Jakes R. (1990) Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 9, 4225–4230.
84. Goedert M., Crowther R. A. and Spillantini M. G. (1998) Tau mutations cause frontotemporal dementias. Neuron 21, 955–958.
85. Goedert M., Jakes R. and Crowther R. A. (1999) Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett. 450, 306–311.
86. Goldman J. S., Farmer J. M., Wood E. M. et al. (2005) Comparison of family histories in FTLD subtypes and related tauopathies. Neurology 65, 1817–1819.
87. Gorno-Tempini M. L., Hillis A. E., Weintraub S. et al. (2011) Classification of primary progressive aphasia and its variants. Neurology 76, 1006–1014.
88. Grover A., Houlden H., Baker M., Adamson J., Lewis J., Prihar G., Pickering-Brown S., Duff K. and Hutton M. (1999) 5′ Splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J. Biol. Chem. 274, 15134–15143.
89. Guerreiro R., Bilgic B., Guven G., Bras J., Rohrer J., Lohmann E., Hanagasi H., Gurvit H. and Emre M. (2013a) Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiol. Aging 34, 2890, e2891–2895.
90. Guerreiro R. J., Lohmann E., Bras J. M. et al. (2013b) Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 70, 78–84.
91. Gustke N., Trinczek B., Biernat J., Mandelkow E. M. and Mandelkow E. (1994) Domains of tau protein and interactions with microtubules. Biochemistry 33, 9511–9522.
92. Han J.-H., Ryu H.-H., Jun M.-H., Jang D.-J. and Lee J.-A. (2012) The functional analysis of the CHMP2B missense mutation associated with neurodegenerative diseases in the endo-lysosomal pathway. Biochem. Biophys. Res. Commun. 421, 544–549.
93. Haston K. M. and Finkbeiner S. (2015) Clinical trials in a dish: the potential of pluripotent stem cells to develop therapies for neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 56, 489–510.
94. Hensman Moss D. J., Poulter M., Beck J. et al. (2014) C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 82, 292–299.
95. Hiscott J. (2007) Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response. Cytokine Growth Factor Rev. 18, 483–490.
96. Holm I. E., Englund E., Mackenzie I. R. A., Johannsen P. and Isaacs A. M. (2007) A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J. Neuropathol. Exp. Neurol. 66, 884–891.
97. Hong M., Zhukareva V., Vogelsberg-Ragaglia V. et al. (1998) Mutation-specific functional impairments in distinct Tau isoforms of hereditary FTDP-17. Science 282, 1914–1917.
98. Hu F., Padukkavidana T., Vaegter C. B., Brady O. A., Zheng Y., Mackenzie I. R., Feldman H. H., Nykjaer A. and Strittmatter S. M. (2010) Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. Neuron 68, 654–667.
99. Huebbers C. U., Clemen C. S., Kesper K. et al. (2007) Pathological consequences of VCP mutations on human striated muscle. Brain 130, 381–393.
100. Hutton M., Lendon C. L., Rizzu P. et al. (1998) Association of missense and 5[prime]-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702–705.
101. Irwin D. J., Cairns N. J., Grossman M., McMillan C. T., Lee E. B., Van Deerlin V. M., Lee V. M. and Trojanowski J. Q. (2015) Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 129, 469–491.
102. Ishiura H. and Tsuji S. (2015) Epidemiology and molecular mechanism of frontotemporal lobar degeneration/amyotrophic lateral sclerosis with repeat expansion mutation in C9orf72. J. Neurogenet. 29, 85–94.
103. Jiao B., Xiao T., Hou L., Gu X., Zhou Y., Zhou L., Tang B., Xu J. and Shen L. (2015) High prevalence of CHCHD10 mutation in patients with frontotemporal dementia from China. Brain, 139, 1–4.
104. Johnson J. O., Glynn S. M., Gibbs J. R. et al. (2014) Mutations in the CHCHD10 gene are a common cause of familial amyotrophic lateral sclerosis. Brain 137, e311.
105. Ju J.-S. and Weihl C. C. (2010) Inclusion body myopathy, Paget's disease of the bone and fronto-temporal dementia: a disorder of autophagy. Hum. Mol. Genet. 19, R38–R45.
106. Kimonis V. E., Mehta S. G., Fulchiero E. C. et al. (2008) Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am. J. Med. Genet. A 146A, 745–757.
107. Kim H. J., Kim N. C., Wang Y. D., et al. (2013) Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495, 467-73.
108. Kleinberger G., Capell A., Haass C. and Van Broeckhoven C. (2013) Mechanisms of granulin deficiency: lessons from cellular and animal models. Mol. Neurobiol. 47, 337–360.
109. Koppers M., Blokhuis A. M., Westeneng H. J. et al. (2015) C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol. 78, 426–438.
110. Kwon I., Xiang S., Kato M. et al. (2014) Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 345, 1139–1145.
111. Laaksovirta H., Peuralinna T., Schymick J. C. et al. (2010) Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study. Lancet Neurol. 9, 978–985.
112. Lagier-Tourenne C., Baughn M., Rigo F. et al. (2013) Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA 110, E4530–E4539.
113. Laird A. S., Van Hoecke A., De Muynck L., Timmers M., Van den Bosch L., Van Damme P. and Robberecht W. (2010) Progranulin is neurotrophic in vivo and protects against a mutant TDP-43 induced axonopathy. PLoS ONE 5, e13368.
114. Lang C. M., Fellerer K., Schwenk B. M., Kuhn P. H., Kremmer E., Edbauer D., Capell A. and Haass C. (2012) Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration. J. Biol. Chem. 287, 19355–19365.
115. Lattante S., Le Ber I., Galimberti D. et al. (2014) Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations and C9orf72 repeat expansions. Neurobiol. Aging 35, 2658, 2655–e2651.
116. Lattante S., Ciura S., Rouleau G. A. and Kabashi E. (2015) Defining the genetic connection linking amyotrophic lateral sclerosis (ALS) with frontotemporal dementia (FTD). Trends Genet. 31, 263–273.
117. Le Ber I., Camuzat A., Hannequin D. et al. (2008) Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. Brain 131, 732–746.
118. Le Ber I., Camuzat A., Guerreiro R. et al. (2013) SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol. 70, 1403–1410.
119. Le Ber I., De Septenville A., Guerreiro R. et al. (2014) Homozygous TREM2 mutation in a family with atypical frontotemporal dementia. Neurobiol. Aging 35, 2419, e2423–2415.
120. Le Ber I., De Septenville A., Millecamps S. et al. (2015) TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts. Neurobiol. Aging 36, 3116,e3115–3118.
121. Leblond C. S., Kaneb H. M., Dion P. A. and Rouleau G. A. (2014) Dissection of genetic factors associated with amyotrophic lateral sclerosis. Exp. Neurol. 262 Pt B, 91–101.
122. Lee S. and Huang E. J. (2015) Modeling ALS and FTD with iPSC-derived neurons. Brain Res. in press.
123. Levine T. P., Daniels R. D., Gatta A. T., Wong L. H. and Hayes M. J. (2013) The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. Bioinformatics 29, 499–503.
124. Liang Y., Gordon E., Rohrer J. et al. (2014) A cognitive chameleon: lessons from a novel MAPT mutation case. Neurocase 20, 684–694.
125. Lill C. M., Rengmark A., Pihlstrom L. et al. (2015) The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimers Dement. 11, 1407–1416.
126. Mackenzie I. R. A. and Neumann M. (2012) FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. Brain Res. 1462, 40–43.
127. Mackenzie I. R., Baborie A., Pickering-Brown S., Du Plessis D., Jaros E., Perry R. H., Neary D., Snowden J. S. and Mann D. M. (2006a) Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol. 112, 539–549.
128. Mackenzie I. R., Baker M., Pickering-Brown S. et al. (2006b) The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 129, 3081–3090.
129. Mackenzie I. R., Neumann M., Baborie A. et al. (2011) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 122, 111–113.
130. Mackenzie I. R., Arzberger T., Kremmer E. et al. (2013) Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 126, 859–879.
131. Majounie E., Abramzon Y., Renton A. E. et al. (2012a) Repeat expansion in C9ORF72 in Alzheimer's disease. N. Engl. J. Med. 366, 283–284.
132. Majounie E., Renton A. E., Mok K. et al. (2012b) Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 11, 323–330.
133. Malkani R., D'Souza I., Gwinn-Hardy K., Schellenberg G. D., Hardy J. and Momeni P. (2006) A MAPT mutation in a regulatory element upstream of exon 10 causes frontotemporal dementia. Neurobiol. Dis. 22, 401–403.
134. Marroquin N., Stranz S., Muller K. et al. (2015) Screening for CHCHD10 mutations in a large cohort of sporadic ALS patients: no evidence for pathogenicity of the p.P34S variant. Brain, 139, 1–3.
135. Maruyama H., Morino H., Ito H. et al. (2010) Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223–226.
136. May S., Hornburg D., Schludi M. H. et al. (2014) C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol. 128, 485–503.
137. McCarthy A., Lonergan R., Olszewska D. A. et al. (2015) Closing the tau loop: the missing tau mutation. Brain 138, 3100–3109.
138. Meisler M. H., Grant A. E., Jones J. M. et al. (2013) C9ORF72 expansion in a family with bipolar disorder. Bipolar Disord. 15, 326–332.
139. Meyer H. and Weihl C. C. (2014) The VCP/p97 system at a glance: connecting cellular function to disease pathogenesis. J. Cell Sci. 127, 3877–3883.
140. Minami S. S., Min S. W., Krabbe G. et al. (2014) Progranulin protects against amyloid beta deposition and toxicity in Alzheimer's disease mouse models. Nat. Med. 20, 1157–1164.
141. Mirra S. S., Murrell J. R., Gearing M. et al. (1999) Tau pathology in a family with dementia and a P301L mutation in tau. J. Neuropathol. Exp. Neurol. 58, 335–345.
142. Mizielinska S. and Isaacs A. M. (2014) C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function? Curr. Opin. Neurol. 27, 515–523.
143. Mizielinska S., Lashley T., Norona F. E., Clayton E. L., Ridler C. E., Fratta P. and Isaacs A. M. (2013) C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 126, 845–857.
144. Mizielinska S., Gronke S., Niccoli T. et al. (2014) C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345, 1192–1194.
145. Momeni P., Rogaeva E., Van Deerlin V. et al. (2006) Genetic variability in CHMP2B and frontotemporal dementia. Neurodegener. Dis. 3, 129–133.
146. Mori K., Arzberger T., Grasser F. A. et al. (2013a) Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 126, 881–893.
147. Mori K., Weng S. M., Arzberger T. et al. (2013b) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335–1338.
148. Morita M., Al-Chalabi A., Andersen P. M. et al. (2006) A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology 66, 839–844.
149. Mukherjee O., Pastor P., Cairns N. J. et al. (2006) HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann. Neurol. 60, 314–322.
150. Neumann M., Sampathu D. M., Kwong L. K. et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133.
151. Neumann M., Rademakers R., Roeber S., Baker M., Kretzschmar H. A. and Mackenzie I. R. (2009) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132, 2922–2931.
152. Neumann M., Bentmann E., Dormann D. et al. (2011) FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134, 2595–2609.
153. Neumann M., Valori C. F., Ansorge O. et al. (2012) Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. Acta Neuropathol. 124, 705–716.
154. Neve R. L., Harris P., Kosik K. S., Kurnit D. M. and Donlon T. A. (1986) Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res. 387, 271–280.
155. Ng A. S. L., Rademakers R. and Miller B. L. (2015) Frontotemporal dementia: a bridge between dementia and neuromuscular disease. Year in Neurology and Psychiatry 1338, 71–93.
156. Nicholson A. M., Finch N. A., Wojtas A. et al. (2013) TMEM106B p. T185S regulates TMEM106B protein levels: implications for frontotemporal dementia. J. Neurochem. 126, 781–791.
157. Nicholson A. M., Finch N. A., Thomas C. S. et al. (2014) Progranulin protein levels are differently regulated in plasma and CSF. Neurology 82, 1871–1878.
158. Onyike C. U. and Diehl-Schmid J. (2013) The epidemiology of frontotemporal dementia. Int. Rev. Psychiatry 25, 130–137.
159. O'Rourke J. G., Bogdanik L., Muhammad A. K. et al. (2015) C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. Neuron 88, 892–901.
160. Paquet D., Bhat R., Sydow A. et al. (2009) A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. J. Clin. Invest. 119, 1382–1395.
161. Peters O. M., Cabrera G. T., Tran H. et al. (2015) Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron 88, 902–909.
162. Petkau T. L. and Leavitt B. R. (2014) Progranulin in neurodegenerative disease. Trends Neurosci. 37, 388–398.
163. Petkau T. L., Neal S. J., Orban P. C., MacDonald J. L., Hill A. M., Lu G., Feldman H. H., Mackenzie I. R. and Leavitt B. R. (2010) Progranulin expression in the developing and adult murine brain. J. Comp. Neurol. 518, 3931–3947.
164. Pickering-Brown S. M., Rollinson S., Du Plessis D., Morrison K. E., Varma A., Richardson A. M. T., Neary D., Snowden J. S. and Mann D. M. A. (2008) Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations. Brain 131, 721–731.
165. Poorkaj P., Bird T. D., Wijsman E. et al. (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815–825.
166. Pottier C., Bieniek K. F., Finch N. et al. (2015) Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 130, 77–92.
167. Proudfoot M., Gutowski N. J., Edbauer D., Hilton D. A., Stephens M., Rankin J. and Mackenzie I. R. (2014) Early dipeptide repeat pathology in a frontotemporal dementia kindred with C9ORF72 mutation and intellectual disability. Acta Neuropathol. 127, 451–458.
168. Puls I., Jonnakuty C., LaMonte B. H. et al. (2003) Mutant dynactin in motor neuron disease. Nat. Genet. 33, 455–456.
169. Quadri M., Cossu G., Saddi V., Simons E. J., Murgia D., Melis M., Ticca A., Oostra B. A. and Bonifati V. (2011) Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson's disease in Sardinia. Neurogenetics 12, 203–209.
170. Rademakers R., Baker M., Gass J. et al. (2007) Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C–>T (Arg493X) mutation: an international initiative. Lancet Neurol. 6, 857–868.
171. Rademakers R., Eriksen J. L., Baker M. et al. (2008) Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum. Mol. Genet. 17, 3631–3642.
172. Rademakers R., Baker M., Nicholson A. M. et al. (2012a) Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat. Genet. 44, 200–205.
173. Rademakers R., Neumann M. and Mackenzie I. R. (2012b) Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 8, 423–434.
174. Rascovsky K., Hodges J. R., Knopman D. et al. (2011) Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456–2477.
175. Ratnavalli E., Brayne C., Dawson K. and Hodges J. R. (2002) The prevalence of frontotemporal dementia. Neurology 58, 1615–1621.
176. Rayaprolu S., Mullen B., Baker M. et al. (2013) TREM2 in neurodegeneration: evidence for association of the p. R47H variant with frontotemporal dementia and Parkinson's disease. Mol. Neurodegener. 8, 19.
177. Rea S. L., Majcher V., Searle M. S. and Layfield R. (2014) SQSTM1 mutations - Bridging Paget disease of bone and ALS/FTLD. Exp. Cell Res. 325, 27–37.
178. Reed L. A., Wszolek Z. K. and Hutton M. (2001) Phenotypic correlations in FTDP-17. Neurobiol. Aging 22, 89–107.
179. Renton A. E., Majounie E., Waite A. et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257–268.
180. Rockenstein E., Overk C. R., Ubhi K. et al. (2015) A Novel Triple Repeat Mutant Tau Transgenic Model That Mimics Aspects of Pick's Disease and Fronto-Temporal Tauopathies. PLoS ONE 10, e0121570.
181. Rohrer J. D., Ahsan R. L., Isaacs A. M. et al. (2009a) Presymptomatic generalized brain atrophy in frontotemporal dementia caused by CHMP2B mutation. Dement. Geriatr. Cogn. Disord. 27, 182–186.
182. Rohrer J. D., Guerreiro R., Vandrovcova J. et al. (2009b) The heritability and genetics of frontotemporal lobar degeneration. Neurology 73, 1451–1456.
183. Rohrer J. D., Isaacs A. M., Mizielinska S. et al. (2015a) C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol. 14, 291–301.
184. Rohrer J. D., Nicholas J. M., Cash D. M. et al. (2015b) Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurol. 14, 253–262.
185. Rollinson S., Mead S., Snowden J. et al. (2011a) Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis. Neurobiol. Aging 32, 758, e751–757.
186. Rollinson S., Rohrer J. D., van der Zee J. et al. (2011b) No association of PGRN 3′UTR rs5848 in frontotemporal lobar degeneration. Neurobiol. Aging 32, 754–755.
187. Rossi G. and Tagliavini F. (2015) Frontotemporal lobar degeneration: old knowledge and new insight into the pathogenetic mechanisms of tau mutations. Front. Aging Neurosci. 7, 192.
188. Rosso S. M., Kaat L. D., Baks T. et al. (2003) Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain 126, 2016–2022.
189. Rubino E., Rainero I., Chio A. et al. (2012) SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 79, 1556–1562.
190. Rutherford N. J., Carrasquillo M. M., Li M. et al. (2012) TMEM106B risk variant is implicated in the pathologic presentation of Alzheimer disease. Neurology 79, 717–718.
191. Sama R. R. K., Ward C. L. and Bosco D. A. (2014) Functions of FUS/TLS from DNA repair to stress response: implications for ALS. ASN Neuro. 6, 4.
192. Sampathu D. M., Neumann M., Kwong L. K. et al. (2006) Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am. J. Pathol. 169, 1343–1352.
193. Schwenk B. M., Lang C. M., Hogl S. et al. (2014) The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes. EMBO J. 33, 450–467.
194. Seelaar H., Kamphorst W., Rosso S. M. et al. (2008) Distinct genetic forms of frontotemporal dementia. Neurology 71, 1220–1226.
195. Shankaran S. S., Capell A., Hruscha A. T., Fellerer K., Neumann M., Schmid B. and Haass C. (2008) Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. J. Biol. Chem. 283, 1744–1753.
196. Shatunov A., Mok K., Newhouse S. et al. (2010) Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol. 9, 986–994.
197. Simon-Sanchez J., Seelaar H., Bochdanovits Z., Deeg D. J., van Swieten J. C. and Heutink P. (2009) Variation at GRN 3′-UTR rs5848 is not associated with a risk of frontotemporal lobar degeneration in Dutch population. PLoS ONE 4, e7494.
198. Siuda J., Fujioka S. and Wszolek Z. K. (2014) Parkinsonian syndrome in familial frontotemporal dementia. Parkinsonism Relat. Disord. 20, 957–964.
199. Skibinski G., Parkinson N. J., Brown J. M. et al. (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 37, 806–808.
200. Sleegers K., Brouwers N., Van Damme P. et al. (2009) Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann. Neurol. 65, 603–609.
201. Smith K. R., Damiano J., Franceschetti S. et al. (2012) Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage. Am. J. Hum. Genet. 90, 1102–1107.
202. Smith B. N., Ticozzi N., Fallini C. et al. (2014) Exome-wide rare variant analysis identifies TUBA4A mutations associated with familial ALS. Neuron 84, 324–331.
203. Snowden J. S., Rollinson S., Thompson J. C. et al. (2012) Distinct clinical and pathological characteristics of frontotemporal dementia associated with C9ORF72 mutations. Brain 135, 693–708.
204. Spillantini M. G., Goedert M., Crowther R. A., Murrell J. R., Farlow M. R. and Ghetti B. (1997) Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments. Proc. Natl Acad. Sci. USA 94, 4113–4118.
205. Spina S., Van Laar A. D., Murrell J. R. et al. (2013) Phenotypic variability in three families with valosin-containing protein mutation. Eur. J. Neurol. 20, 251-+.
206. Stagi M., Klein Z. A., Gould T. J., Bewersdorf J. and Strittmatter S. M. (2014) Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B. Mol. Cell Neurosci. 61, 226–240.
207. Su Z., Zhang Y., Gendron T. F. et al. (2014) Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron 83, 1043–1050.
208. Synofzik M., Maetzler W., Grehl T. et al. (2012) Screening in ALS and FTD patients reveals 3 novel UBQLN2 mutations outside the PXX domain and a pure FTD phenotype. Neurobiol. Aging 33, 2949.e13–2949.e17.
209. Taylor J. P. (2015) Multisystem proteinopathy: intersecting genetics in muscle, bone, and brain degeneration. Neurology 85, 658–660.
210. Therrien M., Rouleau G. A., Dion P. A. and Parker J. A. (2013) Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLoS ONE 8, e83450.
211. Ugwu F., Rollinson S., Harris J., Gerhard A., Richardson A., Jones M., Mann D., Snowden J. and Pickering-Brown S. (2015) A UBQLN2 variant of unknown significance in frontotemporal lobar degeneration. Neurobiol. Aging 36, 546.e15–546.e16.
212. Van Deerlin V. M., Sleiman P. M., Martinez-Lage M. et al. (2010) Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat. Genet. 42, 234–239.
213. Van Kampen J. M., Baranowski D. and Kay D. G. (2014) Progranulin gene delivery protects dopaminergic neurons in a mouse model of Parkinson's disease. PLoS ONE 9, e97032.
214. Vance C., Al-Chalabi A., Ruddy D. et al. (2006) Familial amyotrophic lateral sclerosis with frontotemporal dementia is linked to a locus on chromosome 9p13.2-21.3. Brain 129, 868–876.
215. Vandrovcova J., Anaya F., Kay V., Lees A., Hardy J. and de Silva R. (2010) Disentangling the role of the tau gene locus in sporadic tauopathies. Curr. Alzheimer Res. 7, 726–734.
216. Vilarino-Guell C., Wider C., Soto-Ortolaza A. I. et al. (2009) Characterization of DCTN1 genetic variability in neurodegeneration. Neurology 72, 2024–2028.
217. Wang Y. and Mandelkow E. (2015) Tau in physiology and pathology. Nat. Rev. Neurosci. 17, 22–35.
218. Wang J., Van Damme P., Cruchaga C. et al. (2010) Pathogenic cysteine mutations affect progranulin function and production of mature granulins. J. Neurochem. 112, 1305–1315.
219. Watts G. D. J., Wymer J., Kovach M. J., Mehta S. G., Mumm S., Darvish D., Pestronk A., Whyte M. P. and Kimonis V. E. (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 36, 377–381.
220. Weidberg H. and Elazar Z. (2011) TBK1 mediates crosstalk between the innate immune response and autophagy. Sci. Signal., 4, pe39.
221. Weihl C. C., Dalal S., Pestronk A. and Hanson P. I. (2006) Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum. Mol. Genet. 15, 189–199.
222. Wen X., Tan W., Westergard T. et al. (2014) Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 84, 1213–1225.
223. Wils H., Kleinberger G., Pereson S. et al. (2012) Cellular ageing, increased mortality and FTLD-TDP-associated neuropathology in progranulin knockout mice. J. Pathol. 228, 67–76.
224. Wong T. H., Chiu W. Z., Breedveld G. J. et al. (2014) PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology. Brain 137, 1361–1373.
225. Wong C. H., Topp S., Gkazi A. S. et al. (2015) The CHCHD10 P34S variant is not associated with ALS in a UK cohort of familial and sporadic patients. Neurobiol. Aging 36, 2908, e2917–2908.
226. Wood E. M., Falcone D., Suh E., Irwin D. J., Chen-Plotkin A. S., Lee E. B., Xie S. X., Van Deerlin V. M. and Grossman M. (2013) Development and validation of pedigree classification criteria for frontotemporal lobar degeneration. JAMA Neurol. 70, 1411–1417.
227. Wszolek Z. K., Uitti R. J. and Hutton M. (2000) A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration. Neurology 54, 2028–2030.
228. Xi Z., Rainero I., Rubino E. et al. (2014) Hypermethylation of the CpG-island near the C9orf72 G(4)C(2)-repeat expansion in FTLD patients. Hum. Mol. Genet. 23, 5630–5637.
229. Yin F., Dumont M., Banerjee R. et al. (2010) Behavioral deficits and progressive neuropathology in progranulin-deficient mice: a mouse model of frontotemporal dementia. Faseb. J. 24, 4639–4647.
230. van der Zee J., Gijselinck I., Pirici D., Kumar-Singh S., Cruts M. and Van Broeckhoven C. (2007) Frontotemporal lobar degeneration with ubiquitin-positive inclusions: a molecular genetic update. Neurodegener. Dis. 4, 227–235.
231. van der Zee J., Urwin H., Engelborghs S. et al. (2008) CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro. Hum. Mol. Genet. 17, 313–322.
232. van der Zee J., Van Langenhove T., Kleinberger G. et al. (2011) TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort. Brain 134, 808–815.
233. van der Zee J., Van Langenhove T., Kovacs G. G. et al. (2014) Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta Neuropathol. 128, 397–410.
234. Zhang Y. J., Jansen-West K., Xu Y. F. et al. (2014) Aggregation-prone c9FTD/ALS poly(GA) RAN-translated proteins cause neurotoxicity by inducing ER stress. Acta Neuropathol. 128, 505–524.
235. Zhang M., Xi Z., Zinman L. et al. (2015) Mutation analysis of CHCHD10 in different neurodegenerative diseases. Brain 138, e380.
236. Zhou X., Sun L., Bastos de Oliveira F., Qi X., Brown W. J., Smolka M. B., Sun Y. and Hu F. (2015) Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin. J. Cell Biol. 210, 991–1002.